AbbVie

Open: 174.35 Close: 174.79 Change: 0.44

Can you guess what an AI found about AbbVie.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, year, sale, see, abbvies, earnings, drive, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

Skyrizi and Rinvoq as top TV drug ad spender in 2023. UK National Institute for Health and Care Excellence recommended Tepkinly as a third-line treatment option for adults with relapsed or refractory diffuse large B-cell lymphoma.

Today's News

AbbVie makes a clean sweep with Skyrizi and Rinvoq as top TV drug ad spender in 2023. Pfizer looks to boost flagging paxlovid sales with extra dtc spend | fierce pharma. abbvies. Analysts revamp AbbVie stock price target after earnings report. rick gonzalez lays out plan for internal candidate to take over as abbvies chief. ‘Ozempic face seen driving botox sales, abbvie says (correct). ‘Zempic Face seen driving Botox Sales, AbbVie Says (correct) ‘We do see it as a long-term tailwind.” UK National Institute for Health and Care Excellence recommended AbbVies Tepkinly (epcoritamab) as a third-line treatment option for adults with relapsed or refractory diffuse large B-cell lymphoma. “2024 is an exciting year for AbbVie, as we are well positioned to fully absorb Humira erosion,’ Barclays said. AbbVie sees 2023 sales decline in oncology and immunology. CEO Richard Gonzalez remains bullish on last years performance. AbbVie: 2023 was another outstanding year marked by strong operational execution AbbVie CEO: During the year we meaningfully increased R&D investment and bolstered our pipeline Abbvie broke ground on the US$223 million (S$301 million) expansion of our Singapore manufacturing facility. AbbVie is expected to reach more than $17 billion by 2027, reflecting continued share capture in psoriasis and uptake in inflammatory bowel disease (IBD) New indications have a collective peak sales potential of several billion dollars. AbbVie expects full-year earnings in the range of $11.05-11.25 per share. Shares have increased 8% since the beginning of the year.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, year, sale, see, abbvies, earnings, drive, and the most common words in the summary are: abbvie, market, stock, report, best, price, news, . One of the sentences in the summary was: Skyrizi and Rinvoq as top TV drug ad spender in 2023. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #market #stock #report #best #price #news.